/
NAUT
$1.79-$0.21 (-10.50%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$254.2M
127M shares
52-week range
$0.62 – $4.31
32% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
Borrow rate
0.25%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-8.31
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $2.3M | $2.8M | $3.4M | $5.7M | $6.4M | $6.5M |
| Gross profit | $0 | $0 | −$2.3M | −$2.8M | −$3.4M | −$5.7M | −$6.4M | −$6.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $0 | $8.5M | $10.1M | $26.5M | $36.5M | $47.3M | $50.5M | $41.1M |
| Operating income | −$111.7M | −$10.1M | −$15.7M | −$50.5M | −$63.6M | −$76.2M | −$81.5M | −$66.8M |
| EBITDA | $626.6M | −$9.6M | −$13.3M | −$47.5M | −$54.5M | −$61.8M | −$64.4M | −$52.5M |
| Net income | $626.6M | −$9.6M | −$15.6M | −$50.3M | −$57.9M | −$63.7M | −$70.8M | −$59.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | 87.18 | -1.59 | -0.47 | -0.60 | -0.46 | -0.51 | -0.56 | -0.47 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $700000 | $-0.52 | $-0.52–$-0.51 | 2 |
| 2027 | $8M | $-0.52 | $-0.61–$-0.43 | 2 |
| 2028 | $30M | $-0.43 | $-0.63–$-0.23 | 1 |
| 2029 | $69M | $-0.37 | $-0.55–$-0.19 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Nautilus Biotechnolgy, Inc. Common Stock
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
www.nautilus.bio- Employees
- 130
- IPO / List date
- Jun 10, 2021
- HQ
- SEATTLE, WA
Held by traders on TradeandTell
No one on the platform currently holds NAUT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 265,700 | $1.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NAUT yet.
